Диссертация (1140912), страница 20
Текст из файла (страница 20)
doi:10.1016/j.ctrv.2014.11.003.[Epub ahead of print].39. Cavallaro, U. Cell adhesion and signalling by cadherins and Ig-CAMs incancer / U. Cavallaro, G.C. // Nat. Rev. Cancer. – 2004. – N4. – P. 118–132.40. Chan, J.K. Therapeutic role of lymph node resection in endometrial corpuscancer / J.K. Chan, M.C., W.K. Huh, K.Osann, A.Husain, N.N.Teng et al. // Cancer. –2007. – N107. – P. 1823-1830.41. Chini, E.N. CD38 as a Regulator of Cellular NAD: A Novel PotentialPharmacological Target for Metabolic Conditions / E.N. Chini // Curr Pharm Des. –2009.
– V.15. – P. 57-63.42. Chung, Y.M. Increased Expression of ICAM3 is Associated with RadiationResistance in Cervical Cancer / Y.M. Chung, B.-G. K., C.S. Park, S.J. Huh, J. Kim,J.K. and S. M. C. Park, B.S. Kim, J.S. Kim, Y.D. Yoo, D.-S. Bae // Int. J.
Cancer. –2005. – N117. – P. 194–201.43. Claudio, P.P. RB2/p130 gene-enhanced expression downregulates vascularendothelial growth factor expression and inhibits angiogenesis in vivo / P.P. Claudio,P.S., C.M. Howard et al. // Cancer Res. – 2001. – N61. – P. 462-468.44. Coia, L. The Patterns of Care outcome study for cancer of the uterine cervix/ L. Coia, M.W., R. Lanciano, V.A. Marcial, K. Martz, G. Hanks // Cancer.
– 1990. –N66. – P. 2451.45. Conte, E. Sensitivity of monocytic cells to FAS mediated apoptosis / E.110Conte, L.Manzella, G.Cocchiaro et al. // Scand. J. Immunol. – 2001. – Vol.54. –suppl.1 – P.20-20.46. Countini, P. In vivo apoptosis of CD8–(+) lymphocytes in acute myeloidleukemia patients: involvement of soluble HLAI and Fas ligand / P. Countini // Leukaemia. – 2007. – N21 (2). – P. 253–260.47. Deaglio, S. CD38 at the junction between prognostic marker and therapeutictarget / S. Deaglio, S. Aydin, T. Vaisitti, L.
Bergui, F. Malavasi // Trends Mol. Med. –2008. – V.14. – P. 210-218.48. Deaglio, S. Human CD38: a (r)evolutionary story of enzymes and receptors/ S.Deaglio, K.Mehta, F.Malavasi // Leukemia Research. – 2001. – Vol. 25. – P. 1–12.49. Deaglio, S. The CD38/CD157 mammalian gene family: an evolutionaryparadigm for other leukocyte surface enzymes / S. Deaglio, F. Malavasi // Blood. –2003. – V. 107.
– P. 2392-2399.50. Descamps, P. Predictors of distant recurrence in clinical stage I or II endometrial carcinoma treated by combination surgical and radiation therapy / P.Descamps, G.C., C. Moire, P. Bertrand, M. Castiel, O Le Floch et al. // Gynecol. Oncol.
– 1997. – N64. – P. 54-58.51. Donskov, F. Leukocyte orchestration in blood and tumour tissue followinginterleukin-2ba sed immunotherapy in metastatic renal cell carcinoma / F. Donskov,B.K., Hokland M., et al. // Cancer Immunol. – 2004. – N53. – P. 729-739.52. Eifel, P.J. The influence of tumor size and morphology on the outcome ofpatients with FIGO Stage IB squamous cell carcinoma of the uterine cervix / P.J.
Eifel,M.M., J.T. Wharton, M.J. Oswald // Int. J. Radiat. Oncol. Biol. Phys. – 1993. – N29. –P. 9-16.53. Evans, E. Infiltration of cervical cancer tissue with human papillomavirusspecific cytotoxic T-lymphocytes / E. Evans, M.S., A. Evans, L. Borysiewicz // CancerRes. – 1997. – N57.
– P. 2943-2950.54. Fedele, G. CD38 is expressed on human mature monocyte-derived dendriticcells and is functionally involved in CD83 expression and IL-12 induction / G. Fedele,111F.L., R. Palazzo, E. Ferrero, F. Malavasi, C.M. Ausiello // Eur J Immunol. – 2004. –N34. – P. 1342-1350.55. Ferdeghini, M. Preoperative serum intercellular adhesion molecule-1(ICAM-1) and E-selectin (endothelial cell leukocyte adhesion molecule, ELAM-1) inpatients with epithelial ovarian cancer / M. Ferdeghini, G.A., C. Prontera, C.Annicchiarico, O.
Gagetti, M. Bianchi, V. Facchini, A.R. Genazzani // Anticancer Res.– 1995. – N15. – P. 2255-2260.56. Ferrero, E. The metamorphosis of a molecule: from soluble enzyme to theleukocyte receptor CD38 / E. Ferrero, M.F. // J Leukoc Biol. – 1999. – N65. – P. 151161.57. Focosi, D.
CD57 expression on lymphoma microenvironment as a newprognostic marker related toimmunedysfunction / D. Focosi, P. // JClinOncol. – 2007.– N25. – P. 1289-1291.58. Folsom, A.R. Glycemic Index, Glycemic Load, and Incidence of Endometrial Cancer: The Iowa Women’s Health Study / A.R. Folsom, D.Z., L. Harnack //Nutr. Cancer. – 2003. – N46. – P. 119-124.59. Fox, S.B. The increased expression of adhesion molecules ICAM-3, E- andP-selectins on breast cancer endothelium / S.B. Fox, T. G., K.C. Gatter, A.L. Harris // JPathol. – 1995. – N177 (4). – P. 369-376.60. Franchi, L.
A caspaselike activity is triggered by LPS and is required forsurvival of human dendritic cells / L. Franchi, C.I., B. Tomassini B, C. Nicolo, R. Testi// Blood. – 2003. – N102. – P. 2910-2915.61. Fujimoto, T. Endometrioid uterine cancer: histopathological risk factors oflocal and distant recurrence / T. Fujimoto, N.H., J. Fukuda, A. Nakamura, H. Mizunuma, N. Yaegashi, T. Sugiyama, H. Kurachi, A. Sato, T. Tanaka // Gynecol Oncol. –2009. – N112 (2).
– P. 342-347.62. Geijtenbeek, T.B. DC-SIGN-ICAM-2 interaction mediates dendritic celltrafficking / T.B. Geijtenbeek, D.J.K., D.A. Bleijs, S.J. van Vliet, G.C. van Duijnhoven, V. Grabovsky, R. Alon, C.G. Figdor, Y. van Kooyk // Nat. Immunol. – 2000. –N1. – P. 353–357.11263. Gusberg, S.B. Estrogen and endometrial cancer: an epilogue a la recherchйdu temps perdu / S.B. Gusberg // Gynecol Oncol. – 1994. – N52.
– P. 3-9.64. Hale, G.E. Endometrial cancer: hormonal factors, the perimenopausal “window of risk”, and isoflavones / G.E. Hale, H.C.L., J.M. Cline // J. Clin. Endocrinol.Metabol. – 2002. – N87. – P. 3-15.65. Hara-Yokoyama M., Tetrameric interaction of the ectoenzyme CD38 on thecell surface enables its catalytic and raft-association activities / M. Hara-Yokoyama,M. Kukimoto-Niino, K. Terasawa, S.
Harumiya, K. Podyma-Inoue et al. // Structure. –2012. – V.20. – P. 1585-1595.66. Hazelbag, S. Prognostic relevance of TGF-beta1 and PAI-1 in cervical cancer / S. Hazelbag, K.G., A. Gorter, G.J. Fleuren // Int J Cancer. – 2004. – N112 (6). –P. 1020-1028.67. Hellebrekers, B. Surgically-treated early cervical cancer: prognostic factorsand the significance of depth of tumor invasion / B. Hellebrekers, Z.A., G. Kenter et al.// Int JGynecol Cancer. – 1999. – N9. – P. 212-219.68. Henderson, B.E. Hormonal carcinogenesis / B.E.
Henderson, F. H. S. // Carcinogenesis. – 2000. – N21. – P. 427-433.69. Herrera, F.G. A prospective phase I-II trial of the cyclooxygenase-2 inhibitor celecoxib in patients with carcinoma of the cervix with biomarker assessment ofthe tumor microenvironment / F.G. Herrera, P.C., C. Doll et al. // Int J Radiat OncolBiol Phys. – 2007. – N67. – P.
97–103.70. Hilders, C. Isolation and characterization of tumorinfiltrating lymphocytesfrom cervical carcinoma / C. Hilders, R.L., van Eendenburg J, Y. Nooyen, G.J. Fleuren// Int J Cancer. – 1994. – N57. – P. 805-813.71. Hilders, C. The expression of histocompatibility-related leukocyte antigensin the pathway to cervical carcinoma / C. Hilders, H. J., E. Krul, G.J. Fleuren // AmJClin Pathol. – 1994. – N101. – P. 5-12.72. Hiromatsu, Y.
Increased serum soluble Fas in patients with Graves'disease /Y. Hiromatsu, T. Bednarczuk, E. Soyejima // Thyroid. – 1999. – Vol.9. – P. 341-345.11373. Hohn, H. Human papillomavirus type 33 E7 peptides presented by HLADR*0402 to tumor-infiltrating T cells in cervical cancer / H. Hohn, P.H., S. Gunzel etal. // J Virol. – 2000.
– N74. – P. 6632-6636.74. Huang, M. Prognostic significance of cyclooxygenase-2 in cervical cancer:A meta-analysis / M. Huang, C.Q., J. Xiao, C. Liu, X. Zhao // Int J Cancer. – 2012. –Jun 22. DOI: 10.1002/ijc.27686.75. Jodo,S. Elevated serum levels of soluble FAS/APO-1 (CD95) in patientswith hepatocellular carcinoma / S. Jodo, S. Kobayashi, Y. Nakajima et al. // Clin. Exp.Immunol. – 1998. – Vol.112. – N2. – P.
166-171.76. Kamezaki, S. Serum levels of soluble ICAM-1 and VCAM-1 predict preclinical cancer / S. Kamezaki, K. Y., N. Iwai, T. Hosoda, M. Okamoto, T. Nose // EurJ Cancer. – 2005. – N41 (15). – P. 2355-2359.77. Keys, H.M. A phase III trial of surgery with or without adjunctive externalpelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study / H.M. Keys, J. R., V.L. Brunetto, R.J. Zaino, N.M. Spirtos, J.D.
Bloss et al. // Gynecol. Oncol. – 2004. – N92. – P. 744-751.78. Khudiakova, N.E. Soluble HLA class I and HLA class II antigens in theblood of HIV infected patients / N.E. Khudiakova, V.V. Novikov, G.A. Kravchenko,N.I. Ivanova, I.S. Ptitsyna, N.N. Nosov // Journal of Microbiology, epidemiology andimmunology. – 2004. – N1. – P. 42-45.79. Kim, G.E. Synchronous coexpression of epidermal growth factor receptorand cyclooxygenase-2 in carcinomas of the uterine cervix: A potential predictor ofpoor survival / G.E.
Kim, Y. B. K., N.H. Cho et al. // Clin Cancer Res. – 2004. – N10.– P. 1366-1374.80. Köstler, W.J. Soluble ICAM-1 in breast cancer: clinical significance and biological implications / W.J. Köstler, T. S., T. Brodowicz, A.C. Budinsky, M. Flamm etal. // Cancer Immunol Immunother. – 2001. – N50 (9). – P. 483-490.81. Lai, C-H. Preoperative prognostic variables and the impact of postoperativeadjuvant therapy on the outcomes of stage IB or II cervical carcinoma patients with or114without pelvic lymph node metastasis / C-H Lai, H.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
